Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

Abbott

Endocrinology

Endocrinology Video Recap—December 16, 2025

This biweekly endocrinology video recap covers major regulatory decisions,…

Neuroscience

Neuroscience Today — December 3, 2025

This week’s Neuroscience update highlights advances in seizure therapeutics,…

Cardiovascular

Cardiovascular Today - October 16, 2025

Get the latest on Cardiovascular this week, including key industry…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Neuroscience 2025 Review: Disease Modification Meets Deliverability
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal

Tags

ACLF AI in dermatology AI in HIV Allergic fungal rhinosinusitis antibodies antiviral Avant Technologies Biohacking BioNxt Solutions Cardiac arrhythmias CRO CytoDiffusion EAS 2025 European Union FamilyWell Health Fanconi anemia fibrosis Fingolimod galactosemia Google Quantum AI IDH-mutant glioma Indolent B-cell non Hodgkin lymphoma insulin glargine interoperability Kallyope leukogene therapeutics Metabolic dysfunction associated steatohepatitis Microbiome analysis mitral regurgitation molecular design Mucosal immunity myocardial infarction noom prevention renal stones Respiree retinal ai risankizumab roflumilast 0.05% Skeletalis skin conditions Swissmedic Teva Pharmaceuticals Wave Life Sciences WOMEN Obstetrics & Gynecology

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Neuroscience 2025 Review: Disease Modification Meets Deliverability
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal

TAGS

ACLF AI in dermatology AI in HIV Allergic fungal rhinosinusitis antibodies antiviral Avant Technologies Biohacking BioNxt Solutions Cardiac arrhythmias CRO CytoDiffusion EAS 2025 European Union FamilyWell Health Fanconi anemia fibrosis Fingolimod galactosemia Google Quantum AI IDH-mutant glioma Indolent B-cell non Hodgkin lymphoma insulin glargine interoperability Kallyope leukogene therapeutics Metabolic dysfunction associated steatohepatitis Microbiome analysis mitral regurgitation molecular design Mucosal immunity myocardial infarction noom prevention renal stones Respiree retinal ai risankizumab roflumilast 0.05% Skeletalis skin conditions Swissmedic Teva Pharmaceuticals Wave Life Sciences WOMEN Obstetrics & Gynecology

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy